For patients with potentially reversible renal failure resulting from myeloma but unrelated to hypercalcemia or with ongoing infusion reactions after bisphosphonate infusion, an option is monthly denosumab (given subcutaneously), which, unlike bisphosphonates, is not cleared by the kidneys and does not cause infusion reactions.